AST-032

AST-032 is an investigational small molecule candidate being developed by the South Korean biotechnology company Astrogen for the treatment of Obstructive Sleep Apnea (OSA). The drug is part of Astrogen's research pipeline focusing on neurological and systemic conditions with high unmet medical needs. While the specific molecular target and mechanism of action have not been publicly disclosed, AST-032 is intended to provide a pharmacological approach to managing OSA, a condition characterized by repetitive pauses in breathing during sleep. The candidate is currently in the early stages of development, transitioning from preclinical studies toward clinical evaluation.